Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
48
49
Next >
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
August 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
August 11, 2023
Via
Benzinga
How Is The Market Feeling About Gilead Sciences?
August 10, 2023
Via
Benzinga
2 High-Yield Dividend Stocks to Buy on the Dip
August 08, 2023
The market may have been a bit too harsh on these stocks.
Via
The Motley Fool
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
August 22, 2023
--News Direct--
Via
News Direct
Topics
LGBTQ
Exposures
Diversity
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
August 21, 2023
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.
Via
Benzinga
Exposures
Product Safety
5 Safe Stocks Under $40 to Buy Immediately
August 21, 2023
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now.
Via
InvestorPlace
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
August 04, 2023
GILD earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
August 03, 2023
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs.
Via
Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
July 31, 2023
Via
Benzinga
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
August 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
August 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
August 17, 2023
Via
Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
August 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
The 3 Best Biotech Stocks to Buy in August
August 09, 2023
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.
Via
InvestorPlace
Hypertrophic Cardiomyopathy Therapeutics Market Projected to Show Strong Growth : Novartis, Gilead Sciences, ADVANZ PHARMA
August 08, 2023
Stay up-to-date with Hypertrophic Cardiomyopathy Therapeutics Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
August 04, 2023
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by...
Via
Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
August 04, 2023
Amazon, ELF and CAT were earnings winners, but there were big losers too.
Via
Investor's Business Daily
Gilead Sciences Announces Second Quarter 2023 Financial Results
August 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
August 03, 2023
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.
Via
Benzinga
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
August 01, 2023
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.
Via
InvestorPlace
3 Stocks Retirees Should Absolutely Love
July 29, 2023
These stocks offer solid income plus more.
Via
The Motley Fool
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
July 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
July 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.